Agios Pharmaceuticals Shares Drop 23% Following Novo Nordisk's Positive Trial Results

Agios Pharmaceuticals (NASDAQ: AGIO) shares fell 23% following Novo Nordisk's (NYSE: NVO) announcement of positive phase 3 trial results for its sickle cell treatment, etavopivat. Agios' own trial for mitapavit did not show statistically significant results in reducing sickle cell pain crises, leading to investor concerns.

By Lee Samaha, The Motley Fool Mon, April 20, 2026 at 7:39 PM GMT+3 3 min read · Yahoo Finance · April 20, 2026, 16:39 UTC

Tickers: $AGIO $NVO

Topics: clinical trial outcomes pharmaceutical competition sickle cell disease stock price movement

Read the full article at Yahoo Finance

More Health news

Eli Lilly Shares Rise Following Positive Clinical Trial Results for Retatrutide and Foundayo Motley Fool · November 12, 2026, 17:15 UTC
Data Suggests United States May Lose Measles Elimination Status The Verge · November 11, 2026, 19:48 UTC
Rising U.S. Measles Outbreaks Pose Significant Economic Burden CNBC · November 11, 2026, 12:00 UTC
FDA Issues Not Approvable Letter for NovoCure's Optune Mya Motley Fool · November 10, 2026, 18:50 UTC
Immunovant Reports Q2 2026 Financial Results and IMVT-1402 Clinical Data Motley Fool · November 10, 2026, 01:43 UTC
Royalty Pharma Poised to Benefit from Revolution Medicines' FDA-Approved Pancreatic Cancer Drug Motley Fool · November 8, 2026, 15:15 UTC
Acumen Pharmaceuticals Expects Phase II Alzheimer's Trial Results in November 2026 Motley Fool · November 5, 2026, 01:48 UTC
Moderna and Merck Face Manufacturing Challenges for Promising Personalized Cancer Vaccine Motley Fool · November 3, 2026, 20:52 UTC
Amgen's Imdelltra Shows Significant Efficacy in Advanced Lung Cancer Treatment Motley Fool · November 2, 2026, 17:25 UTC
American Association for Physician Leadership Releases New Book on Systems Thinking and Strategic Change PR Newswire · October 30, 2026, 12:51 UTC